NASDAQ$XWEL
XpresSpa Group Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Announced second quarter 2021 financial results and provided business update.
XpresSpa Group reported $9.1 million in total revenue, including $8.7 million from XpresCheck, and significantly reduced its Adjusted EBITDA loss and net loss compared to the previous year. The company is expanding its services with the Treat brand and re-opening legacy XpresSpa locations.
- MSA practice patient fees increased to $17.1 million in Q2 from $6.3 million in Q1.
- Net loss narrowed to $4.7 million compared to $58.5 million in the prior year's second quarter.
- Strong liquidity position with an unrestricted cash balance of $102.5 million.
- Launched Phase 2 of Treat™ and plans to launch Phase 3 this fall.
Headline financials
Revenue & EPS history
XpresSpa · Revenue · Quarterly
$9.09M
Revenue by segment
XpresSpa · $6.64M total across 3 segments · Q1 2026
- XpresSpa$4.2M—63.2%
- XpresTest$1.92M—28.9%
- Naples Wax$524K—7.9%
Forward guidance
The company is focused on expanding its three sustainable growth brands, leveraging its corporate structure and airport relationships to increase market share and shareholder value.
Tailwinds
- Re-opening an additional eight to ten legacy XpresSpa locations this fall.
- Launching Phase 3 of Treat this fall at JFK and Phoenix airports.
- Belief that COVID-19 testing will remain important due to variants and international travel requirements.
- Encouraging results after re-opening first four XpresSpa locations.
- Potential for accretive acquisitions and strategic transactions.
Headwinds
- Start-up costs associated with XpresCheck and Treat.
- Additional legal fees related to XpresSpa litigation matters.
- Reduced variable costs related to closed XpresSpa locations.
- Uncertainties around the cash flows of XpresCheck.
- Potential impact of COVID-19 variants on travel and testing demand.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2021
+1.1%
Avg return
Earnings day
-2.3%
Avg return
5 days after
-4.5%
Avg return
30 days after
43%
16 / 37 earnings
Positive
+24.4%
Q4 2019
Best reaction
-11.1%
Q4 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | — | — | — | |
| Q3 2025 | +0.0% | -8.4% | -9.6% | |
| Q2 2025 | -5.8% | -8.3% | -8.3% | |
| Q1 2025 | +1.2% | +12.8% | +9.3% | |
| Q4 2024 | +0.0% | +0.0% | +15.4% | |
| Q3 2024 | -1.2% | -10.6% | -24.1% | |
| Q2 2024 | +3.7% | +0.5% | -14.8% | |
| Q1 2024 | +3.4% | -8.4% | +41.6% | |
| Q4 2023 | +0.0% | +0.7% | +32.1% | |
| Q3 2023 | +6.2% | +35.4% | +31.1% | |
| Q2 2023 | -4.2% | -4.2% | -25.0% | |
| Q1 2023 | +0.0% | +4.2% | +4.2% | |
| Q4 2022 | +6.3% | -9.4% | -21.9% | |
| Q3 2022 | +0.0% | -12.3% | -10.5% | |
| Q2 2022 | -6.5% | -5.4% | +9.7% | |
| Q1 2022 | -1.1% | -18.7% | -22.0% | |
| Q4 2021 | +8.2% | +52.0% | +11.2% | |
| Q3 2021 | +11.7% | +13.1% | +25.5% | |
| Q2 2021 | -6.9% | -13.1% | -2.9% | |
| Q4 2020 | +6.4% | -3.5% | -20.8% | |
| Q3 2020 | -1.1% | -13.4% | -22.5% | |
| Q2 2020 | -6.5% | -4.2% | -42.9% | |
| Q1 2020 | -7.5% | -5.5% | +6.5% | |
| Q4 2019 | +24.4% | +26.8% | +17.1% | |
| Q3 2019 | +2.0% | -5.9% | -41.6% | |
| Q2 2019 | +0.0% | +21.2% | +31.9% | |
| Q1 2019 | +7.8% | -9.0% | -40.0% | |
| Q4 2018 | +0.3% | -12.0% | -22.7% | |
| Q3 2018 | +0.0% | +0.0% | +11.1% | |
| Q2 2018 | +0.0% | -25.0% | -20.0% | |
| Q1 2018 | -4.8% | -31.7% | -20.6% | |
| Q4 2017 | -11.1% | -24.7% | -17.3% | |
| Q3 2017 | -0.8% | -4.0% | -6.5% | |
| Q2 2017 | +11.5% | +4.4% | +9.7% | |
| Q1 2017 | +4.9% | +1.9% | +5.6% | |
| Q4 2016 | +0.9% | -9.7% | -20.8% | |
| Q3 2016 | +0.8% | -8.0% | -15.6% | |
| Q2 2016 | -1.9% | -1.0% | +1.9% | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — | |
| Q4 2011 | — | — | — | |
| Q3 2011 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro